Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia.

Neurology · 2023 · PMC10074464 · PMID 36517235

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

For the LS mean (95% CI) changes from baseline in index values (0.0287 [−0.0009 to 0.0583]) and VAS scores (6.2 [2.0–10.4]) of the EQ-5D-5L, the mirogabalin group showed a trend toward improvement over the placebo group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.